Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

miR-4708ÀÇ multidrug resistance protein-1 ¹ßÇö Á¶ÀýÀ» ÅëÇÑ paclitaxel ¹Î°¨¼º Áõ°¡

miR-4708 Enhances Paclitaxel Sensitivity through Modulating Expression of Multidrug Resistance Protein-1

´ëÇѱ¸°­¾Ç¾È¸éº´¸®ÇÐȸÁö 2017³â 41±Ç 2È£ p.55 ~ 62
ÃÖÀå¿­, À¯Áö¿ø, ¾È»ó°Ç,
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖÀå¿­ ( Choi Jang-Yeol ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­º´¸®Çб³½Ç
À¯Áö¿ø ( Ryu Ji-Won ) - Á¶¼±´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°­³»°úÇб³½Ç
¾È»ó°Ç ( Ahn Sang-Gun ) - Á¶¼±´ëÇб³ Ä¡°ú´ëÇÐ ±¸°­º´¸®Çб³½Ç

Abstract


Multidrug resistance (MDR) remains one of the most significant obstacles in various cancer treatment, and this process often involves dysregulation of the number of micro-RNAs. The aim of this study was to explore the role of miR-4708 on the regulation of MDR-1 expression and the regulation of multidrug resistance (MDR) to chemotherapeutic drugs. Luciferase reporter assays demonstrated that miR-4708 directly binds MDR-1 3¡¯-UTR and down-regulated reporter luciferase activity. The mRNA and protein expression levels of MDR1 were significantly decreased following miR-4708 overexpression. Additionally, the accumulation of rhodamine-123 in paclitacel resistant FaDu cells following miR-4708 transfection was significantly increased compared with control, indicating that the efflux capacity was reduced. These results demonstrated that miR-4708 could be involved in the regulation of MDR via targeting MDR-1 and may provide a potential strategy for reversing drug resistance in oral cancer.

Å°¿öµå

miR-4708; FaDu; MDR1; Paclitaxel

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI